Effects of ATP-sensitive potassium channel opener on potassium transport and alveolar fluid clearance in the resected human lung.
Since the effect of an ATP-sensitive potassium channel (KATP channel) opener on the function of alveolar epithelial cells is unknown, the effect of YM934, a newly synthesized KATP channel opener, on potassium influx into the alveolar spaces and alveolar fluid clearance was determined in the resected human lung. An isosmolar albumin solution with a low potassium concentration was instilled into the distal airspaces of resected human lungs. Alveolar fluid clearance was measured by the progressive increase in alveolar protein concentration. Net potassium transport was measured by the change in potassium concentration and alveolar fluid volume. YM934 (10(-4) M) increased net influx of potassium by 140% into the alveolar spaces and also increased alveolar fluid clearance by 60% in the experiments with a potassium concentration of 0.3 mEq/1. Glibenclamide (10(-4) M), a KATP channel blocker, inhibited the YM934-increased influx of potassium transport and the increase in alveolar fluid clearance. Also amiloride (10(-5) M), an inhibitors of apical sodium uptake, blocked the YM934 stimulated increase in net alveolar fluid clearance. These results indicate that a KATP channel opener can effect potassium transport and net vectorial fluid movement across the human alveolar epithelium.
Sakuma
T
T
Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan.
Takahashi
K
K
Ohya
N
N
Nakada
T
T
Matthay
M A
MA
D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000368:Aged; D000584:Amiloride / Q000494:pharmacology; D048588:Benzoxazines; D001826:Body Fluids / Q000378:metabolism*; D003497:Cyclic N-Oxides / Q000494:pharmacology*; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism; D005110:Extracellular Space / Q000378:metabolism; D005905:Glyburide / Q000494:pharmacology; D006801:Humans; D017136:Ion Transport; D008168:Lung; D008875:Middle Aged; D010078:Oxazines / Q000494:pharmacology*; D011013:Pneumonectomy; D011188:Potassium / Q000378:metabolism*; D015221:Potassium Channels / Q000187:drug effects*; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism*
D048588:Benzoxazines; D003497:Cyclic N-Oxides; D010078:Oxazines; D015221:Potassium Channels; D000584:Amiloride; D000255:Adenosine Triphosphate; D011188:Potassium; D005905:Glyburide; C084963:2H-1,4-benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, N-oxide